Lars-Olof Hattenbach

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4921582/publications.pdf

Version: 2024-02-01

61 papers

1,749 citations

279701 23 h-index 302012 39 g-index

74 all docs

74 docs citations

times ranked

74

1628 citing authors

#	Article	IF	CITATIONS
1	Switching to intravitreal fluocinolone acetonide implant for refractory diabetic macular edema: 12-and 24-month results. European Journal of Ophthalmology, 2022, 32, 443-449.	0.7	4
2	Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 1843-1856.	1.0	12
3	The significance of pigment epithelial detachment in central serous chorioretinopathy. European Journal of Ophthalmology, 2021, 31, 556-565.	0.7	7
4	Factors predicting normal visual acuity following anatomically successful macular hole surgery. Acta Ophthalmologica, 2021, 99, e324-e329.	0.6	24
5	The urgency of surgical treatment for rhegmatogenous retinal detachment. Ophthalmologe, 2021, 118, 160-165.	0.4	O
6	Ophthalmic Outpatient and Inpatient Care Under Pandemic Conditions: Hygiene, Triage and New Challenges. Klinische Monatsblatter Fur Augenheilkunde, 2021, 238, 561-568.	0.3	3
7	Impact of the SARS-CoV-2 pandemic on ophthalmic care in Germany. Ophthalmologe, 2021, 118, 166-175.	0.4	16
8	Pneumatic retinopexy: A critical reappraisal. Survey of Ophthalmology, 2021, 66, 585-593.	1.7	15
9	Surgical Management of Choroidal Diseases. Klinische Monatsblatter Fur Augenheilkunde, 2021, 238, 980-987.	0.3	О
10	Authors' Response to correspondence: Pneumatic retinopexy–a critical reappraisal. Survey of Ophthalmology, 2021, 66, 900-901.	1.7	0
11	Authors' Response. Survey of Ophthalmology, 2021, 66, 1076-1078.	1.7	0
12	Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: Post-hoc Analysis from the COMRADE Trials. Current Eye Research, 2020, 45, 604-614.	0.7	3
13	Headâ€toâ€head comparison of ranibizumab PRN versus singleâ€dose dexamethasone for branch retinal vein occlusion (COMRADEâ€B). Acta Ophthalmologica, 2018, 96, e10-e18.	0.6	48
14	Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1â€year results of the <scp>COMRADE</scp> extension study. Acta Ophthalmologica, 2018, 96, e933-e941.	0.6	22
15	Sphingosine Kinase 2 Modulates Retinal Neovascularization in the Mouse Model of Oxygen-Induced Retinopathy., 2018, 59, 653.		14
16	Minimally Invasive Surgical Treatment of Macular Hemorrhages. , 2018, , 33-47.		0
17	Prothrombin polymorphism A19911G, factor V HR2 haplotype A4070G, and plasminogen activator-inhibitor-1 polymorphism 4G/5G and the risk of retinal vein occlusion. Ophthalmic Genetics, 2017, 38, 413-417.	0.5	10
18	Intravitreal Sustained-Release Steroid Implants for the Treatment of Macular Edema following Surgical Removal of Epiretinal Membranes. Ophthalmologica, 2017, 237, 232-237.	1.0	28

#	Article	IF	CITATIONS
19	Platelet activation by ADP is increased in selected patients with anterior ischemic optic neuropathy or retinal vein occlusion. Platelets, 2017, 28, 720-723.	1.1	11
20	Elevated lipoprotein (a) levels are an independent risk factor for retinal vein occlusion. Acta Ophthalmologica, 2017, 95, 140-145.	0.6	12
21	Reply. American Journal of Ophthalmology, 2016, 169, 292-293.	1.7	2
22	Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study. American Journal of Ophthalmology, 2016, 169, 258-267.	1.7	66
23	Selective Thrombophilia Screening in Young Patients with Retinal Artery Occlusion. Ophthalmologica, 2016, 235, 189-194.	1.0	8
24	Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (<scp>RABAMES</scp>): sixâ€month results of a prospective randomized clinical trial. Acta Ophthalmologica, 2015, 93, e29-37.	0.6	45
25	Retrospective, Observational Study in Patients Receiving a Dexamethasone Intravitreal Implant 0.7 mg for Macular Oedema Secondary to Retinal Vein Occlusion. Ophthalmologica, 2015, 233, 18-26.	1.0	13
26	Intravitreal Ranibizumab versus Isovolemic Hemodilution in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized, Multicenter Trial. Ophthalmologica, 2015, 233, 8-17.	1.0	6
27	Experimental Endoscopic Endovascular Cannulation: A Novel Approach to Thrombolysis in Retinal Vessel Occlusion., 2012, 53, 42.		7
28	Course of Intraocular Pressure after Intravitreal Injection of 0.05 mL Ranibizumab (Lucentis < \hat{A}^{\otimes} < /sup >). European Journal of Ophthalmology, 2010, 20, 174-179.	0.7	58
29	Coagulation disorders and the risk of retinal vein occlusion. Thrombosis and Haemostasis, 2010, 103, 299-305.	1.8	56
30	Electrophysiological Retinal Pigment Epithelium Changes Observed with Indocyanine Green, Trypan Blue and Triamcinolone. Ophthalmic Research, 2010, 44, 17-23.	1.0	9
31	Subretinal Hemorrhages Associated with Age-Related Macular Degeneration in Patients Receiving Anticoagulation or Antiplatelet Therapy. American Journal of Ophthalmology, 2010, 149, 316-321.e1.	1.7	53
32	Optical Coherence Tomography for Diagnosis of Posterior Vitreous Detachment at the Macular Region. European Journal of Ophthalmology, 2009, 19, 442-447.	0.7	21
33	Selective thrombophilia screening of patients with nonarteritic anterior ischemic optic neuropathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 485-490.	1.0	21
34	Incidence of posterior vitreous detachment after cataract surgery. Journal of Cataract and Refractive Surgery, 2009, 35, 987-991.	0.7	62
35	RETINAL VEIN OCCLUSION AND LOW-DOSE FIBRINOLYTIC THERAPY (R.O.L.F.). Retina, 2009, 29, 932-940.	1.0	35
36	Risk Factors for Complications After Congenital Cataract Surgery without Intraocular Lens Implantation in the First 18 Months of Life. American Journal of Ophthalmology, 2008, 146, 1-7.e1.	1.7	97

#	Article	IF	Citations
37	Intravenous Thrombolysis With Low-dose Recombinant Tissue Plasminogen Activator in Central Retinal Artery Occlusion. American Journal of Ophthalmology, 2008, 146, 700-706.e1.	1.7	110
38	Retinal Vascular Occlusions. Deutsches Ärzteblatt International, 2008, 105, 474-9.	0.6	20
39	Expression of Ubiquitin Carboxy-Terminal Hydrolase-L1 in Photocoagulated Human Retinal Pigment Epithelial Cells. Current Eye Research, 2007, 32, 367-372.	0.7	2
40	Retinal Vein Occlusion Associated With Antithrombin Deficiency Secondary to a Novel G9840C Missense Mutation. JAMA Ophthalmology, 2006, 124, 1165.	2.6	6
41	Reactivation of Toxoplasma Retinochoroiditis Under Atovaquone Therapy in an Immunocompetent Patient. Ocular Immunology and Inflammation, 2006, 14, 185-187.	1.0	47
42	Massive subhyaloidal hemorrhage associated with severe PAI-1 deficiency. Graefe's Archive for Clinical and Experimental Ophthalmology, 2005, 243, 963-966.	1.0	15
43	Experimental Percutaneous Cannulation of the Supraorbital Arteries: Implication for Future Therapy., 2005, 46, 1557.		27
44	Intraocular Levels of Methotrexate after Oral Low-Dose Treatment in Chronic Uveitis. Ophthalmologica, 2005, 219, 54-55.	1.0	10
45	Pigment-Epithelium-Derived Factor Is Upregulated in Photocoagulated Human Retinal Pigment Epithelial Cells. Ophthalmic Research, 2005, 37, 341-346.	1.0	42
46	Pigment Epithelium Endoscopic Laser Surgery for Treatment of Choroidal Neovascularization. Ophthalmologica, 2004, 218, 162-175.	1.0	10
47	Factor XII deficiency: A thrombophilic risk factor for retinal vein occlusion. American Journal of Ophthalmology, 2004, 137, 459-464.	1.7	65
48	Recurrent retinal vein occlusion in a patient with increased plasma levels of histidine-rich glycoprotein. American Journal of Ophthalmology, 2003, 135, 232-234.	1.7	23
49	tPA and gas in submacular hemorrhage: Author reply. Ophthalmology, 2002, 109, 825.	2.5	0
50	Detection of Inducible Nitric Oxide Synthase and Vascular Endothelial Growth Factor in Choroidal Neovascular Membranes. Ophthalmologica, 2002, 216, 209-214.	1.0	33
51	High prevalence of resistance to APC in young patients with retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology, 2002, 240, 163-168.	1.0	49
52	Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells. Investigative Ophthalmology and Visual Science, 2002, 43, 2799-805.	3.3	14
53	Central Retinal Vein Occlusion and Nonarteritic Ischemic Optic Neuropathy in 2 Patients with Mild Iron Deficiency Anemia. Ophthalmologica, 2001, 215, 128-131.	1.0	41
54	Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions. Ophthalmology, 2001, 108, 1485-1492.	2.5	150

#	Article	IF	CITATIONS
55	Intraocular recombinant tissue-plasminogen activator fibrinolysis of fibrin formation after cataract surgery in children. Journal of Cataract and Refractive Surgery, 1999, 25, 357-362.	0.7	32
56	Ophthalmic manifestation of congenital protein C deficiency. Journal of AAPOS, 1999, 3, 188-190.	0.2	33
57	Visual Outcome after Treatment with Low-Dose Recombinant Tissue Plasminogen Activator or Hemodilution in Ischemic Central Retinal Vein Occlusion. Ophthalmologica, 1999, 213, 360-366.	1.0	41
58	VITREOUS CONCENTRATIONS OF TPA AND PLASMINOGEN ACTIVATOR INHIBITOR ARE ASSOCIATED WITH VEGF IN PROLIFERATIVE DIABETIC VITREORETINOPATHY. Retina, 1999, 19, 383-389.	1.0	11
59	VITREOUS CONCENTRATIONS OF TPA AND PLASMINOGEN ACTIVATOR INHIBITOR ARE ASSOCIATED WITH VEGF IN PROLIFERATIVE DIABETIC VITREORETINOPATHY. Retina, 1999, 19, 383.	1.0	33
60	Fibrinolytic Therapy with Low-Dose Recombinant Tissue Plasminogen Activator in Retinal Vein Occlusion. Ophthalmologica, 1998, 212, 394-398.	1.0	45
61	Identification of Beta-Defensins in Human Conjunctiva. Antimicrobial Agents and Chemotherapy, 1998, 42, 3332-3332.	1.4	20